Recombinant Cynomolgus MS4A1 Protein, His-tagged, Alexa Fluor 555 conjugated
Cat.No. : | MS4A1-62CAF555 |
Product Overview : | Alexa Fluor 555 conjugated recombinant Cynomolgus MS4A1 (F7D2Q2) (Glu213-Pro297), fused with a polyhistidine tag at the C-terminus, was produced in Human Cells. |
Availability | October 14, 2024 |
Unit | |
Price | |
Qty |
- Specification
- Gene Information
- Related Products
- Download
Source : | HEK293 |
Species : | Monkey |
Tag : | His |
Form : | Lyophilized |
Molecular Mass : | The recombinant cynomolgus CD20 comprises 96 amino acids and has a calculated molecular mass of 11.2 kDa. The apparent molecular mass of it is approximately 24-27 and 18 kDa in SDS-PAGE under reducing conditions. |
Protein length : | 96 |
N-terminal Sequence Analysis : | Glu 213 |
Endotoxin : | < 1.0 EU/ μg of the protein as determined by the LAL method. |
Purity : | (97.6+1.4) % as determined by SDS-PAGE |
Characteristic : | Disulfide-linked homodimer Labeled with Alexa Fluor 555 via amines With an excitation and emission maximum of 555/565 nm, Alexa Fluor 555 can be efficiently excited using a 543 nm He-Ne laser line and detected under standard TRITC/Cy3 filters. |
Stability : | Samples are stable for up to 12 months from date of receipt at -70 centigrade. |
Storage : | Store it under sterile conditions at -20 to -70 centigrade. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles. |
Storage Buffer : | Lyophilized from sterile PBS, pH 7.4. Normally 5%-8% trehalose and mannitol are added as protectants before lyophilization. |
Reconstitution : | It is recommended that sterile water be added to the vial to prepare a stock solution. Centrifuge the vial at 4 centigrade before opening to recover the entire contents. |
Gene Name : | MS4A1membrane-spanning 4-domains, subfamily A, member 1 [Macaca fascicularis(crab-eating macaque) ] |
Official Symbol : | MS4A1 |
Gene ID : | 102118491 |
mRNA Refseq : | NM_001287312 |
Protein Refseq : | NP_001274241 |
Products Types
◆ Recombinant Protein | ||
MS4A1-5732M | Recombinant Mouse MS4A1 Protein, His (Fc)-Avi-tagged | +Inquiry |
MS4A1-09F | Recombinant Ferret MS4A1 protein(Glu213-Pro297), His-tagged | +Inquiry |
MS4A1-20H | Recombinant Human MS4A1 protein(204-291 aa), GST-tagged | +Inquiry |
MS4A1-432D | Recombinant Dog MS4A1 protein, His&Myc-tagged | +Inquiry |
Ms4a1-830M | Recombinant Mouse Ms4a1 Protein, MYC/DDK-tagged | +Inquiry |
◆ Lysates | ||
MS4A1-1848FCL | Recombinant Ferret MS4A1 cell lysate | +Inquiry |
MS4A1-819CCL | Recombinant Cynomolgus MS4A1 cell lysate | +Inquiry |
MS4A1-1542HCL | Recombinant Human MS4A1 cell lysate | +Inquiry |
Related Gene
For Research Use Only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative BioMart.
Inquiry
- Reviews
- Q&As
Customer Reviews (3)
Write a reviewIts strong affinity allows for robust binding to target proteins, thereby enhancing the accuracy of analysis.
Surpassing expectations, it significantly amplifies the results of my research.
The operational guidelines for this reagent are readily comprehensible and accessible, facilitating seamless implementation of experiments, even for individuals lacking prior expertise.
Q&As (7)
Ask a questionMS4A1 expression is tightly regulated during different stages of B-cell development. It is absent in early B-cell progenitors and gradually increases during maturation. MS4A1 expression is upregulated upon B-cell activation and can be influenced by various cytokines and signaling pathways. This tightly controlled expression pattern ensures proper B-cell development, while aberrant regulation may contribute to B-cell disorders or malignancies.
MS4A1 expression levels have been explored as potential diagnostic or prognostic markers for certain B-cell disorders. Quantification of CD20 expression by immunohistochemistry or flow cytometry can aid in the diagnosis and classification of B-cell malignancies. Additionally, low CD20 expression levels have been associated with resistance to CD20-targeted therapies, serving as a prognostic indicator in B-cell lymphomas.
While CD20-targeted antibodies have revolutionized the treatment of B-cell malignancies, further therapeutic strategies are being explored. These include enhancing CD20 internalization, using antibody-drug conjugates, and developing novel targeted therapies based on the signaling pathways associated with MS4A1. Investigating these approaches may provide alternative treatments and improve outcomes for patients with B-cell disorders.
MS4A1 helps maintain immune tolerance by preventing the production of autoreactive B cells. It contributes to the elimination of self-reactive B cell clones through mechanisms such as antibody-dependent cellular cytotoxicity and antibody-mediated phagocytosis. MS4A1 dysregulation, however, can lead to the production of autoantibodies and the development of autoimmune diseases. Understanding the fine-tuned regulation of MS4A1's functions is essential for maintaining immune homeostasis and preventing autoimmunity.
MS4A1 interacts with multiple proteins, such as tetraspanins, Src-family kinases, and lipid rafts, which form a complex network involved in B-cell signaling. Upon ligand binding, MS4A1 activates intracellular signaling pathways, including PI3K/Akt and MAPK/ERK, which regulate B-cell survival, proliferation, and differentiation. Understanding these pathways and their crosstalk with MS4A1 can provide insights into B-cell activation and potential therapeutic targets.
The MS4A1 protein, also known as CD20, is a tetraspanin membrane protein found predominantly in B cells. It plays a crucial role in B-cell development, activation, and antibody production. Structurally, CD20 consists of four transmembrane domains and a large extracellular loop. Functionally, it regulates B-cell signaling by promoting calcium influx upon B-cell receptor activation, modulating cell cycle progression, and facilitating antibody-mediated cytotoxicity.
MS4A1 dysregulation has been implicated in B-cell malignancies, including non-Hodgkin lymphomas and leukemia. Increased expression or altered signaling of MS4A1 may promote survival and proliferation of malignant B cells. CD20-targeted therapies, such as monoclonal antibodies, have been successfully employed in treating B-cell malignancies, highlighting the significance of MS4A1 as a therapeutic target in these diseases.
Ask a Question for All MS4A1 Products
Required fields are marked with *
My Review for All MS4A1 Products
Required fields are marked with *
Inquiry Basket